Predictors of Psychological Health in Myasthenia Gravis

  • Robert H. Paul
  • Paola García-Egan
Part of the Current Clinical Neurology book series (CCNEU)


The chapter examines mental health in patients with myasthenia gravis (MG). Relatively few investigational studies have explored this area of patient care, with the most rigorous studies centered on cognitive manifestations. These studies reveal cognitive difficulties in a subset of patients, with a strong correspondence to mental fatigue. A small number of studies report elevated anxiety in MG but no major increase in depression, and no studies have clearly linked mental health with disease onset or progression. Ongoing disease severity is only modestly correlated with psychological distress and quality of life, though individuals with greater physical disability report more severe disruption in daily living activities. The chapter reviews four key predictors of psychological well-being in chronic disease (uncertainty, control, illness intrusiveness, social support) and pathways to optimize these factors in the clinical setting. Professionals involved in the care of MG play an important role in facilitating the mental health and quality of life of their patients. Incorporating mental health assessment and support into routine clinical practice empowers patients to achieve the best possible outcomes and life quality.


Myasthenia gravis Fatigue Cognition Neuropsychology Social support Quality of life Psychological health Uncertainty in illness Illness intrusiveness Perceived control 


  1. 1.
    Paul RH, Cohen RA, Zawacki T, Gilchrist JM, Aloia MS. What have we learned about cognition in myasthenia gravis? A review of methods and results. Neurosci Biobehav Rev. 2001;25:75–81.CrossRefPubMedGoogle Scholar
  2. 2.
    Mao Z, Yin J, Lu Z, Hu X. Association between myasthenia gravis and cognitive function: a systematic review and meta-analysis. Ann Indian Acad Neurol. 2015;18(2):131–7.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Ochs C, Bradley J, Katholi CR, Byl NN, Brown VM, Jones LL, et al. Symptoms of patients with myasthenia gravis receiving treatment. J Med. 1988;29:1–12.Google Scholar
  4. 4.
    Carter SL, Rourke SB, Murji S, Shore D, Rourke BP. Cognitive complaints, depression, medical symptoms, and their association with neuropsychological functioning in HIV infection: a structural equation model analysis. Neuropsychology. 2003;17(3):410–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Paul RH, Cohen RA, Gilchrist J, Aloia MS, Goldstein JM. Cognitive dysfunction in individuals with myasthenia gravis. J Neurol Sci. 2000;179:59–64.CrossRefPubMedGoogle Scholar
  6. 6.
    Benedict RHB, Weinstock-Guttman B, Fishman I, Sharma J, Tjoa CW, Bakshi R. Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Arch Neurol. 2004;61(2):226–30.CrossRefPubMedGoogle Scholar
  7. 7.
    Green J, McDonald WM, Vitek JL, Evatt M, Freeman A, Haber M, et al. Cognitive impairments in advanced PD without dementia. Neurology. 2002;59(9):1320–4.CrossRefPubMedGoogle Scholar
  8. 8.
    Bäckman L, Robins-Wahlin TB, Lundin A, Ginovart N, Farde L. Cognitive deficits in Huntington’s disease are predicted by dopaminergic PET markers and brain volumes. Brain. 1997;120(12):2207–17.CrossRefPubMedGoogle Scholar
  9. 9.
    Whiting J, Cooper J, Lindstrom JM. Antibodies in sera from patients with myasthenia gravis do not bind to nicotinic acetylcholine receptors from human brain. J Neuroimmunol. 1987;16:205–13.CrossRefPubMedGoogle Scholar
  10. 10.
    Keesey JC. Does myasthenia affect the brain? J Neurol Sci. 1999;170:77–89.CrossRefPubMedGoogle Scholar
  11. 11.
    Kluger BM, Krupp LB, Enoka RM. Fatigue and fatigability in neurologic illnesses proposal for a unified taxonomy. Neurology. 2013;80(4):409–16.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Sneddon J. Myasthenia gravis: a study of social, medical, and emotional problems in 26 patients. Lancet. 1980;1(8167):526–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Grohar-Murray ME, Becker A, Reilly S, Ricci M. Self-care actions to manage fatigue among myasthenia gravis patients. J Neurosci Nurs. 1998;30:191–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Elsais A, Wyller VB, Loge JH, Kerty E. Fatigue in myasthenia gravis: is it more than muscular weakness? BMC Neurol. 2013;13(1):132.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Steptoe A, Bolton J. The short-term influence of high and low intensity physical exercise on mood. Psychol Health. 1988;2:91–106.CrossRefGoogle Scholar
  16. 16.
    Fiske AD, Schneider W. Controlled and automatic processing during tasks requiring sustained attention: a new approach to vigilance. Hum Factors. 1981;23:737–50.CrossRefGoogle Scholar
  17. 17.
    Paul RH, Cohen RA, Gilchrist J. Ratings of subjective mental fatigue relates to cognitive performance in patients with myasthenia gravis. J Clin Neurosci. 2002;9:243–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Symonette CJ, Watson BV, Koopman WJ, Nicolle MW, Doherty TJ. Muscle strength and fatigue in patients with generalized myasthenia gravis. Muscle Nerve. 2010;41(3):362–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Jordan B, Schweden TL, Mehl T, Menge U, Zierz S. Cognitive fatigue in patients with myasthenia gravis. Muscle Nerve. 2017;56(3):449–57.CrossRefPubMedGoogle Scholar
  20. 20.
    Paul RH, Cohen RA, Gilchrist J, Goldstein J. Fatigue and its impact on patients with myasthenia gravis. Muscle Nerve. 2000;23:1402–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Jefferson AL, Paul RH, Ozonoff AL, Cohen RA. Evaluating elements of executive functioning as predictors of instrumental activities of daily living (IADLs). Arch Clin Neuropsychol. 2006;21(4):311–20.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Cahn-Weiner DA, Farias ST, Julian L, Harvey DJ, Kramer JH, Reed BR, et al. Cognitive and neuroimaging predictors of instrumental activities of daily living. J Int Neuropsychol Soc. 2007;13(05):747–57.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Boyle PA, Paul RH, Moser DJ, Cohen RA. Executive impairments predict functional declines in vascular dementia. Clin Neuropsychol. 2004;18(1):75–82.CrossRefPubMedGoogle Scholar
  24. 24.
    Phillips LH. The epidemiology of myasthenia gravis. Ann N Y Acad Sci. 2003;998:407–12.CrossRefPubMedGoogle Scholar
  25. 25.
    Sherwood L. Human physiology: from cells to systems. 2nd ed. New York: West Publishing Company; 1993.Google Scholar
  26. 26.
    Blalock JE, Smith EM. A complete regulatory loop between the immune and neuroendocrine systems. Fed Proc. 1985;44:108–11.PubMedGoogle Scholar
  27. 27.
    Maes M, Bosmans E, Meltzer HY. Immunoendocrine aspects of major depression. Relationships between plasma interleukin-6 and soluble interleukin-2 receptor, prolactin and cortisol. Eur Arch Psychiatry Clin Neurosci. 1995;245:172–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Meyer E. Psychological disturbances in myasthenia gravis: a predictive study. Ann N Y Acad Sci. 1966;135:417–23.CrossRefPubMedGoogle Scholar
  29. 29.
    Martin RD, Flegenheimer WV. Psychiatric aspects of the management of the myasthenic patient. Mt Sinai J Med. 1971;38:594–601.PubMedGoogle Scholar
  30. 30.
    Shinkai K, Ohmori O, Ueda N, Nakamura J, Amano T, Tsuji S. A case of myasthenia gravis preceded by major depression. J Neuropsychiatry Clin Neurosci. 2001;13:116–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Chafetz ME. Psychological disturbances in myasthenia gravis. Ann N Y Acad Sci. 1966;135:424–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Dube SR, Fairweather D, Pearson WS, Felitti VJ, Anda RF, Croft JB. Cumulative childhood stress and autoimmune diseases in adults. Psychosom Med. 2009;71(2):243–50.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Danese A, Pariante CM, Caspi A, Taylor A, Poulton R. Childhood maltreatment predicts adult inflammation in a life-course study. Proc Natl Acad SciU S A. 2007;104:1319–24.CrossRefGoogle Scholar
  34. 34.
    Danese A, Moffitt TE, Harrington H, Milne BJ, Polanczyk G, Pariante CM, et al. Adverse childhood experiences and adult risk factors for age-related disease: depression, inflammation, and clustering of metabolic risk markers. Arch Pediatr Adolesc Med. 2009;163(12):1135–43.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Schwartz ML, Cahill R. Psychopathology associated with myasthenia gravis and its treatment by psychotherapeutically oriented group counseling. J Chronic Dis. 1971;24:543–52.CrossRefPubMedGoogle Scholar
  36. 36.
    MacKenzie KR, Martin MH, Howard FM. Myasthenia gravis: psychiatric concomitants. Can Med Assoc J. 1969;100:988–91.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Santy PA. Underdiagnosed myasthenia gravis in emergency psychiatric referrals. Ann Emerg Med. 1983;12:397–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Beydoun SR, Wang J, Levine RL, Farvid A. Emotional stress as a trigger of myasthenic crisis and concomitant takotsubo cardiomyopathy: a case report. J Med Case Rep. 2010;4(1):393.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Kleinman A. The illness narratives. New York: Basic Books; 1988.Google Scholar
  40. 40.
    Richards HS, Jenkinson E, Rumsey N, Harrad RA. The psychosocial impact of ptosis as a symptom of myasthenia gravis: a qualitative study. Orbit. 2014;33(4):263–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Paradis CM, Friedman S, Lazar RM, Kula RW. Anxiety disorders in a neuromuscular clinic. Am J Psychiatry. 1993;150:1102–4.CrossRefPubMedGoogle Scholar
  42. 42.
    Magni G, Micaglio GF, Lalli R, Bejato L, Candeago MR, Merskey H, Angelini C. Psychiatric disturbances associated with myasthenia gravis. Acta Psychiatr Scand. 1988;77:443–5.CrossRefPubMedGoogle Scholar
  43. 43.
    Paul RH, Cohen RA, Goldstein J, Gilchrist J. Severity of mood, self-evaluative and vegetative symptoms in myasthenia gravis. J Neuropsychiatry Clin Neurosci. 2000;12:499–501.CrossRefPubMedGoogle Scholar
  44. 44.
    Paul RH, Nash JM, Cohen RA, Gilchrist JM, Goldstein JM. Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve. 2001;24:512–6.CrossRefPubMedGoogle Scholar
  45. 45.
    Sabre L, Westerberg E, Liik M, Punga AR. Diversity in mental fatigue and social profile of patients with myasthenia gravis in two different Northern European countries. Brain Behav. 2017;7(4):e00653.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Ybarra MI, Kummer A, Frota ERC, Oliveira JTD, Gomez RS, Teixeira AL. Psychiatric disorders in myasthenia gravis. Arq Neuropsiquiatr. 2011;69(2A):176–9.CrossRefPubMedGoogle Scholar
  47. 47.
    Nyenhuis DL, Rao SM, Zajecka JM, Luchetta T, Bernardin L, Garron DC. Mood disturbance versus other symptoms of depression in multiple sclerosis. JINS. 1995;1:291–6.PubMedGoogle Scholar
  48. 48.
    Brown ES, Suppes T. Mood symptoms during corticosteroid therapy: a review. Harv Rev Psychiatry. 1998;5:239–46.CrossRefPubMedGoogle Scholar
  49. 49.
    Hoffmann S, Ramm J, Grittner U, Kohler S, Siedler J, Meisel A. Fatigue in myasthenia gravis: risk factors and impact on quality of life. Brain Behav. 2016;6(10):e00538.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Cioncoloni D, Casali S, Ginanneschi F, Carone M, Veronica B, Rossi A, et al. Major motor-functional determinants associated with poor self-reported health-related quality of life in myasthenia gravis patients. Neurol Sci. 2016;37(5):717–23.CrossRefPubMedGoogle Scholar
  51. 51.
    Raggi A, Schiavolin S, Leonardi M, Antozzi C, Baggi F, Maggi L, et al. Development of the MG-DIS: an ICF-based disability assessment instrument for myasthenia gravis. Disabil Rehabil. 2014;36(7):546–55.CrossRefPubMedGoogle Scholar
  52. 52.
    Padua L, Evoli A, Aprile I, Caliandro P, Mazza S, Padua R, et al. Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci. 2001;22:363–9.CrossRefPubMedGoogle Scholar
  53. 53.
    Rostedt A, Padua L, Stalberg EV. Correlation between regional myasthenic weakness and mental aspects of quality of life. Eur J Neurol. 2006;13:191–3.CrossRefPubMedGoogle Scholar
  54. 54.
    House JS, Landis KR, Umberson D. Social relationships and health. Science. 1988;241:540–4.CrossRefPubMedGoogle Scholar
  55. 55.
    Mishel MH. Reconceptualization of the uncertainty in illness theory. J Nurs Scholarsh. 1990;22:256–62.CrossRefGoogle Scholar
  56. 56.
    Mishel MH. Perceived uncertainty and stress in illness. Res Nurs Health. 1984;7:163–71.CrossRefPubMedGoogle Scholar
  57. 57.
    Mishel MH, Braden CJ. Uncertainty: a mediator between support and adjustment. West J Nurs Res. 1987;9:43–57.CrossRefPubMedGoogle Scholar
  58. 58.
    Bennett SJ. Relationships among selected antecedent variables and coping effectiveness in postmyocardial infarction patients. Res Nurs Health. 1993;16:131–9.CrossRefPubMedGoogle Scholar
  59. 59.
    Mullins LL, Cote MP, Fuemmeler BF, Jean VM, Beatty WW, Paul RH. Illness intrusiveness, uncertainty, and distress in individuals with multiple sclerosis. Rehabil Psychol. 2001;46:139–53.CrossRefGoogle Scholar
  60. 60.
    Mishel MH, Sorenson DS. Uncertainty in gynecological cancer: a test of the mediating functions of mastery and coping. Nurs Res. 1991;40:167–71.PubMedGoogle Scholar
  61. 61.
    Mast ME. Adult uncertainty in illness: a critical review of research. Sch Inq Nurs Pract. 1995;9:3–23.PubMedGoogle Scholar
  62. 62.
    Braden CJ, Mishel MH, Longman AJ, Burns LR. Self-help intervention project: women receiving treatment for breast cancer. Cancer Pract. 1998;6:87–98.CrossRefPubMedGoogle Scholar
  63. 63.
    Badger TA, Braden C, Mishel MH. Depression burden, self-help interventions, and side effect experience in women receiving treatment for breast cancer. Oncol Nurs Forum. 2001;28:567–74.PubMedGoogle Scholar
  64. 64.
    Mishel MH, Belyea M, Germino BB, Stewart JL, Bailey DE Jr, Robertson C, et al. Helping patients with localized prostate cancer manage uncertainty and treatment side effects: nurse delivered psycho-educational intervention via telephone. Cancer. 2002;94(6):1854–66.CrossRefPubMedGoogle Scholar
  65. 65.
    Mishel MH, Germino BB, Belyea M, Stewart JL, Bailey DE Jr, Mohler J, et al. Moderators of outcomes from an uncertainty management intervention for men with localized prostate cancer. Nurs Res. 2003;52(2):89–97.CrossRefPubMedGoogle Scholar
  66. 66.
    Mishel MH, Germino BB, Gil KM, Belyea M, Laney IC, Stewart J, et al. Benefits from an uncertainty management intervention for African-American and Caucasian older long-term breast cancer survivors. Psychooncology. 2005;14:962–78.CrossRefPubMedGoogle Scholar
  67. 67.
    Devins GM, Binik YM, Hutchinson TA, Hollomby DJ, Barre PE, Guttmann RD. The emotional impact of end-stage renal disease: importance of patients’ perceptions of intrusiveness and control. Int J Psychiatry Med. 1983–1984;13:327–43.CrossRefPubMedGoogle Scholar
  68. 68.
    Devins GM. Illness intrusiveness and the psychosocial impact of lifestyle disruptions in chronic life-threatening disease. Adv Ren Replace Ther. 1994;1:251–63.CrossRefPubMedGoogle Scholar
  69. 69.
    Devins GM, Seland TP, Klein GM, Edworthy SM, Saary MJ. Stability and determinants of psychosocial well-being in multiple sclerosis. Rehabil Psychol. 1993;38:11–26.CrossRefGoogle Scholar
  70. 70.
    Devins GM. Illness intrusiveness and the psychosocial impact of end-stage renal disease. In: Hadry MA, Kiernan J, Kutscher AH, Cahill L, Bevenitsky AI, editors. Psychosocial aspects of end-stage renal disease: issues of our times. New York: Haworth Press; 1991. p. 83–102.Google Scholar
  71. 71.
    Devins GM, Shnek ZM. Multiple sclerosis. In: Frank RG, Elliott TR, editors. Handbook of rehabilitation psychology. Washington, DC: American Psychological Association; 2000. p. 163–84.CrossRefGoogle Scholar
  72. 72.
    Devins GM, Stam HJ, Koopmans JP. Psychosocial impact of laryngectomy mediated by perceived stigma and illness intrusiveness. Can J Psychiatry. 1994;39:608–16.CrossRefPubMedGoogle Scholar
  73. 73.
    Hough ES, Brumitt GA, Templin TN. Social support, demands of illness, and depression in chronically ill urban women. Health Care Women Int. 2000;20:349–62.Google Scholar
  74. 74.
    Cott CA, Gignac MAM, Badley EM. Determinants of self-rated health for Canadians with chronic disease and disability. J Epidemiol Community Health. 1999;53:731–6.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Brown GW, Andrews B, Harris T, Adler Z, Bridge L. Social support, self-esteem and depression. Psychol Med. 1986;6:238–47.Google Scholar
  76. 76.
    Holahan CK, Holahan CJ. Self-efficacy, social support, and depression in aging: a longitudinal analysis. J Gerontol. 1987;42(1):65–8.CrossRefPubMedGoogle Scholar
  77. 77.
    Schreurs KMG, de Ridder DT. Integration of coping and social support perspectives: implications for the study of adaptation to chronic diseases. Clin Psychol Rev. 1997;17:89–112.CrossRefPubMedGoogle Scholar
  78. 78.
    Smith CA, Dobbins CJ, Wallston KA. The mediational role of perceived competence in psychological adjustment to rheumatoid arthritis. J Appl Soc Psychol. 1991;21:1218–47.CrossRefGoogle Scholar
  79. 79.
    Blixen CE, Kippes C. Depression, social support, and quality of life in older adults with osteoarthritis. Image J Nurs Sch. 1999;31:221–6.CrossRefPubMedGoogle Scholar
  80. 80.
    Raggi A, Leonardi M, Mantegazza R, Casale S, Fioravanti G. Social support and self-efficacy in patients with Myasthenia Gravis: a common pathway towards positive health outcomes. Neurol Sci. 2010;31(2):231–5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Missouri Institute of Mental HealthBerkleyUSA
  2. 2.Department of Psychological SciencesUniversity of Missouri, St. LouisSaint LouisUSA

Personalised recommendations